ArticleBMC women's health2025
Evaluation of the long-term efficacy and safety of dydrogesterone in the treatment of endometriosis/dysmenorrhea.
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEndometriosis is currently considered a chronic disease for which long-term medical treatment is needed. The aim of this study was to evaluate the long-term efficacy and safety of dydrogesterone in Chinese women with endometriosis and dysmenorrhea in a real-world setting.
methodsThis was a retrospective study of endometriosis or dysmenorrhea patients who required conservative treatment and who were treated with 10 mg oral dydrogesterone twice a day for 21 consecutive days for 12 consecutive cycles at Shaanxi Provincial People's Hospital from May 2020 to October 2021. Changes in endometriotic lesion volume, dysmenorrhea, SF-36 score, menstrual status, and haemoglobin and Ca125 levels from baseline were measured. The volume change was calculated as follows: [(baseline lesion volume-lesion volume at follow-up)/baseline lesion volume]*100%. Changes > 15%, ± 15%, and >-15% were defined as lesions that were reduced, unchanged, and increased, respectively. Dysmenorrhea was assessed by means of visual analogue scale (VAS) scores. Wilcoxon signed-rank tests were performed to estimate the changes in the above aspects before and after treatment.
resultsThis study included 48 patients with endometriosis or dysmenorrhea aged 25 to 47 years, and 38 patients completed 12 cycles of medication and follow-up. Forty-five patients had endometriotic lesions, among whom 38 (84.44%) had smaller or unchanged lesions and 7 (15.56%) had enlarged lesions. The endometriotic lesion volume changed from 65.73 ± 67.89 cm
conclusionDydrogesterone can effectively control endometriotic lesions in most women and significantly improve dysmenorrhea and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.